At Shanghai Children's Medical Center, a girl recently underwent a scar-free robotic splenectomy using the SHURUI® single-port surgical system—marking her family’s third generation to battle hereditary spherocytosis with surgery.
Her father had a 20 cm open-surgery scar from decades ago. Her older brother, seven years prior, had a laparoscopic splenectomy, leaving four small scars. Now, thanks to SHURUI®'s minimally invasive robotic platform, her procedure required only a 3 cm umbilical incision, hidden in the belly button.
This family’s story reflects the evolution of surgical care in China—from open to laparoscopic to ultra-minimally invasive robotic procedures. With SHURUI®’s flexible snake-like instruments and 3D precision, surgeons can achieve better cosmetic and clinical outcomes—especially critical in pediatric care.
As SHURUI® system expands to complex cases like choledochal cysts and pancreatic tumors, it continues to reshape the future of pediatric surgery—one tiny incision at a time.
Important Notes
The Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has been approved by the National Medical Products Administration (NMPA) in China for urology and gynecology laparoscopic surgeries. Surgeons who wish to learn the surgical operations of the SHURUI robot should contact Beijing Surgerii Robotics Co., Ltd. to participate in the official training program. Patients who want to participate in the registered clinical trials of the SHURUI robot should contact the official cooperative hospitals of Surgerii and consult with surgeons to determine their suitability for surgery with the SHURUI robot. Both surgeons and patients should carefully understand all information regarding the performance of surgeries by the SHURUI robot and its potential risks.
Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other
trademarks and may not be used without permission.
